Dipyridamole and Nicardipine Interaction
Drug interaction information between Dipyridamole and Nicardipine.
Dipyridamole and Nicardipine have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Dipyridamole and Nicardipine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
These drugs do not change how nicardipine attaches to proteins in the blood.
What To Do
No specific dose changes are required based on this information, but you should keep your doctor informed.
FDA Label Information
When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine hydrochloride capsules were not altered.
Dipyridamole Also Interacts With
- Heparin moderate
- Warfarin moderate
- Adenosine minor
- Enoxaparin minor
Nicardipine Also Interacts With
- Digoxin major
- Nirmatrelvir/Ritonavir moderate
- Tacrolimus Topical moderate
- Furosemide minor
- Propranolol minor
Frequently Asked Questions
Can I take Dipyridamole and Nicardipine together?
This is a minor interaction. No specific dose changes are required based on this information, but you should keep your doctor informed.
How serious is the interaction between Dipyridamole and Nicardipine?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Dipyridamole and Nicardipine interact?
These drugs do not change how nicardipine attaches to proteins in the blood.
Understanding the Dipyridamole and Nicardipine Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Dipyridamole belongs to the Antiplatelet / Vasodilator class and Nicardipine belongs to the Calcium Channel Blocker class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These drugs do not change how nicardipine attaches to proteins in the blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Dipyridamole has 5 total documented interactions on file in this dataset, and Nicardipine has 14. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: No specific dose changes are required based on this information, but you should keep your doctor informed. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Dipyridamole or Nicardipine based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.